Denmark · Delayed Price · Currency is DKK Trifork Group AG Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered 8% organic growth and 27% EBITDA growth, driven by a product-led strategy and strong public sector wins. Product revenue rose to 45% of total, with margins improving and guidance maintained for 7%-11% organic growth for the year.
Fiscal Year 2025
-
Record 2025 revenue of EUR 221 million with 7% organic growth and strong margin improvement, driven by a shift toward product-led solutions and robust demand for AI, data hosting, and digital health. 2026 guidance targets EUR 230–240 million revenue and 15–17% EBITDA margin.
-
Q3 saw 25% growth in platforms and products, strong public sector wins, and improved margins. Full-year revenue is set to break records, with EBITDA close to historic highs and cost savings fully realized in Q4.
-
Revenue grew 5.1% in Q2 and 9.5% for H1 2025, with strong Run segment growth offsetting declines in Build and Inspire. Full-year guidance is maintained, with H2 expected to deliver higher revenue and margins through cost savings and pipeline conversion.
-
Q1 2025 saw 14.1% revenue growth and record-high recurring revenue, driven by a shift to a product-led model and key public sector wins. Margins are set to improve in H2 as cost savings take effect, with guidance maintained despite macro risks.
Fiscal Year 2024
-
2024 delivered modest growth with Q4 improvement, but full-year revenue declined slightly due to weak Q2/Q3. 2025 guidance targets 10%-15% growth, supported by cost savings and a product-led strategy, with U.S. and Labs segments as key drivers.
-
Revenue and EBITDA for 2024 are expected to be flat or lower year-over-year, with a EUR 10 million cost-saving program underway. Strong growth in the US and public sector Denmark offsets declines in other segments, while new AI and spatial computing platforms drive innovation.
-
Q2 2024 saw a 7% organic revenue decline and lower margins due to market softness and reduced customer activity, but full-year growth of 5% is still expected. New public sector contracts and Labs segment growth support a positive outlook for 2025-2027.